Search research articles
Contact Us
Filters
Showing results (211-220 of 226) with videos related to
Page
of 23
Sort By:
Bladder Cancer (Amsterdam, Netherlands)
|
March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>
Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
The Lancet. Oncology
|
March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Amar U Kishan, Yilun Sun, Alison C Tree, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 3, 2014
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity
Gillian C Barnett, Deborah Thompson, Laura Fachal, et al.
European Urology Oncology
|
June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative
Jan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Frontiers in Oncology
|
October 5, 2020
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy
Sophie R de Mol van Otterloo, John P Christodouleas, Erwin L A Blezer, et al.
Journal of the National Cancer Institute
|
May 17, 2019
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
Sarah L Kerns, Laura Fachal, Leila Dorling, et al.
Nature Reviews. Clinical Oncology
|
June 2, 2016
Clinical development of new drug-radiotherapy combinations
Ricky A Sharma, Ruth Plummer, Julie K Stock, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 226) with videos related to
Sort By:
Page
of 23
Bladder Cancer (Amsterdam, Netherlands)
|
March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>
Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
The Lancet. Oncology
|
March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Amar U Kishan, Yilun Sun, Alison C Tree, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 3, 2014
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity
Gillian C Barnett, Deborah Thompson, Laura Fachal, et al.
European Urology Oncology
|
June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative
Jan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Frontiers in Oncology
|
October 5, 2020
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy
Sophie R de Mol van Otterloo, John P Christodouleas, Erwin L A Blezer, et al.
Journal of the National Cancer Institute
|
May 17, 2019
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
Sarah L Kerns, Laura Fachal, Leila Dorling, et al.
Nature Reviews. Clinical Oncology
|
June 2, 2016
Clinical development of new drug-radiotherapy combinations
Ricky A Sharma, Ruth Plummer, Julie K Stock, et al.
Page
of 23